Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease.

Cools R, Lewis SJ, Clark L, Barker RA, Robbins TW.

Neuropsychopharmacology. 2007 Jan;32(1):180-9. Epub 2006 Jul 12.

2.

Dopamine and performance in a reinforcement learning task: evidence from Parkinson's disease.

Shiner T, Seymour B, Wunderlich K, Hill C, Bhatia KP, Dayan P, Dolan RJ.

Brain. 2012 Jun;135(Pt 6):1871-83. doi: 10.1093/brain/aws083. Epub 2012 Apr 15.

3.

l-DOPA changes ventral striatum recruitment during motor sequence learning in Parkinson's disease.

Kwak Y, Müller ML, Bohnen NI, Dayalu P, Seidler RD.

Behav Brain Res. 2012 Apr 21;230(1):116-24. doi: 10.1016/j.bbr.2012.02.006. Epub 2012 Feb 10.

PMID:
22343069
4.

Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET.

Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM.

Brain. 2002 Mar;125(Pt 3):584-94.

PMID:
11872615
5.

Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.

Fera F, Nicoletti G, Cerasa A, Romeo N, Gallo O, Gioia MC, Arabia G, Pugliese P, Zappia M, Quattrone A.

Brain Res Bull. 2007 Sep 14;74(1-3):75-83. Epub 2007 Jun 6.

PMID:
17683792
6.

Focusing effects of L-dopa in Parkinson's disease.

Ng B, Palmer S, Abugharbieh R, McKeown MJ.

Hum Brain Mapp. 2010 Jan;31(1):88-97. doi: 10.1002/hbm.20847.

PMID:
19585587
7.

Levodopa-sensitive, dynamic changes in effective connectivity during simultaneous movements in Parkinson's disease.

Palmer SJ, Eigenraam L, Hoque T, McCaig RG, Troiano A, McKeown MJ.

Neuroscience. 2009 Jan 23;158(2):693-704. doi: 10.1016/j.neuroscience.2008.06.053. Epub 2008 Jul 3.

PMID:
18722512
8.

Brain dopaminergic modulation associated with executive function in Parkinson's disease.

Farid K, Sibon I, Guehl D, Cuny E, Burbaud P, Allard M.

Mov Disord. 2009 Oct 15;24(13):1962-9. doi: 10.1002/mds.22709.

PMID:
19672989
9.

L-dopa medication in Parkinson's disease restores activity in the motor cortico-striatal loop but does not modify the cognitive network.

Jubault T, Monetta L, Strafella AP, Lafontaine AL, Monchi O.

PLoS One. 2009 Jul 7;4(7):e6154. doi: 10.1371/journal.pone.0006154.

10.

The role of dopamine in cognitive sequence learning: evidence from Parkinson's disease.

Shohamy D, Myers CE, Grossman S, Sage J, Gluck MA.

Behav Brain Res. 2005 Jan 30;156(2):191-9.

PMID:
15582105
11.

Reversal learning in Parkinson's disease depends on medication status and outcome valence.

Cools R, Altamirano L, D'Esposito M.

Neuropsychologia. 2006;44(10):1663-73. Epub 2006 May 26.

PMID:
16730032
12.

Levodopa influences striatal activity but does not affect cortical hyper-activity in Parkinson's disease.

Martinu K, Degroot C, Madjar C, Strafella AP, Monchi O.

Eur J Neurosci. 2012 Feb;35(4):572-83. doi: 10.1111/j.1460-9568.2011.07979.x. Epub 2012 Feb 3.

PMID:
22304628
13.

Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands.

Cools R, Barker RA, Sahakian BJ, Robbins TW.

Cereb Cortex. 2001 Dec;11(12):1136-43.

PMID:
11709484
14.

Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.

Cools R.

Neurosci Biobehav Rev. 2006;30(1):1-23. Epub 2005 Jun 1. Review.

PMID:
15935475
15.

Pharmacologically modulated fMRI--cortical responsiveness to levodopa in drug-naive hemiparkinsonian patients.

Buhmann C, Glauche V, Stürenburg HJ, Oechsner M, Weiller C, Büchel C.

Brain. 2003 Feb;126(Pt 2):451-61.

PMID:
12538411
16.

Prefrontal alterations in Parkinson's disease with levodopa-induced dyskinesia during fMRI motor task.

Cerasa A, Pugliese P, Messina D, Morelli M, Gioia MC, Salsone M, Novellino F, Nicoletti G, Arabia G, Quattrone A.

Mov Disord. 2012 Mar;27(3):364-71. doi: 10.1002/mds.24017. Epub 2011 Nov 10.

PMID:
22076870
17.

Levodopa reinstates connectivity from prefrontal to premotor cortex during externally paced movement in Parkinson's disease.

Herz DM, Siebner HR, Hulme OJ, Florin E, Christensen MS, Timmermann L.

Neuroimage. 2014 Apr 15;90:15-23. doi: 10.1016/j.neuroimage.2013.11.023. Epub 2013 Nov 22.

18.

Apathy in Parkinson's disease is associated with nucleus accumbens atrophy: a magnetic resonance imaging shape analysis.

Carriere N, Besson P, Dujardin K, Duhamel A, Defebvre L, Delmaire C, Devos D.

Mov Disord. 2014 Jun;29(7):897-903. doi: 10.1002/mds.25904. Epub 2014 May 10.

PMID:
24817690
19.

Subthalamic nucleus stimulation modulates motor cortex oscillatory activity in Parkinson's disease.

Devos D, Labyt E, Derambure P, Bourriez JL, Cassim F, Reyns N, Blond S, Guieu JD, Destée A, Defebvre L.

Brain. 2004 Feb;127(Pt 2):408-19. Epub 2003 Dec 22.

PMID:
14691060
20.

Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose L-dopa.

Eltayb A, Wadenberg ML, Svensson TH.

Biol Psychiatry. 2005 Aug 15;58(4):337-43.

PMID:
16102547

Supplemental Content

Support Center